Gyre Therapeutics (FRA:L9S) Price-to-Free-Cash-Flow : (As of Jun. 09, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-09), Gyre Therapeutics's share price is €9.80. Gyre Therapeutics does not have enough years/quarters to calculate the Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023. Therefore GuruFocus does not calculate Price-to-Free-Cash-Flow Ratio at this moment.

The historical rank and industry rank for Gyre Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:L9S' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 42.17 Med: 66.01 Max: 401.08
Current: 42.17

During the past 3 years, Gyre Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 401.08. The lowest was 42.17. And the median was 66.01.

FRA:L9S's Price-to-Free-Cash-Flow is ranked worse than
59.26% of 216 companies
in the Biotechnology industry
Industry Median: 30.545 vs FRA:L9S: 42.17

Gyre Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was €0.24.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Gyre Therapeutics was 255.40% per year.

Gyre Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Gyre Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Price-to-Free-Cash-Flow Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Free-Cash-Flow

97.68

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Price-to-Free-Cash-Flow	-	-	97.68

Competitive Comparison of Gyre Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Gyre Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Price-to-Free-Cash-Flow falls into.

Gyre Therapeutics Price-to-Free-Cash-Flow Calculation

Gyre Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	9.80	/
	=

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

Gyre Therapeutics (FRA:L9S) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Gyre Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (FRA:L9S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (FRA:L9S) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

GYRE:USA

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (FRA:L9S) Headlines

No Headlines